Repeat Motif-containing Regions within Thyroglobulin*

Jaemin Lee and Peter Arvan

From the Division of Metabolism, Endocrinology, and Diabetes, the University of Michigan Medical Center, Ann Arbor, Michigan 48109-0678

Thyroglobulin (precursor for thyroid hormone synthesis) is a large secreted glycoprotein comprising contiguous region I (multiple type-1 repeating units engaging the first ~1,191 residues, followed by a ~245-residue hinge region), regions II-III (multiple type-2 and 3 repeating units, comprising ~720 residues), and the C-terminal cholinesterase-like (ChEL) domain (~570 residues). A signal peptide attached to ChEL makes an independent secretory protein that binds to I-II-III, stabilizing it and rescuing the secretion of I-II-III that would otherwise be trapped in the endoplasmic reticulum (ER). In this study, we found that a signal peptide attached to regions II-III also makes for an efficient secretory protein that neither demonstrably interacts nor has its secretion enhanced by the presence of secretory ChEL. By contrast, region I, either with or without the hinge region, cannot be secreted on its own and remains in the ER where it is bound to ER chaperones BiP and GRP94. Whereas ChEL can rescue secretion of I-II-III, it can rescue I-II only very weakly, and region I not at all. Yet, ChEL begins to rescue region I in cells that also co-express secretory II-III. The data suggest that conformational maturation of region I is a limiting step in the thyroglobulin maturation process, and this step is facilitated by the presence of both regions II-III and ChEL. Mutations causing hypothyroidism might induce solely local/regional misfolding or may interfere more globally by impeding interactions between regions that are required for thyroglobulin secretion.

In vertebrates, thyroid hormones are first created in the apical luminal cavity of follicles of the thyroid gland, upon iodination of the thyroglobulin (Tg)1 protein (1, 2). It is the structure of Tg (3, 4) rather than the specificity of the peroxidase (5) that is thought to catalyze the coupling of di-iodotyrosyl residues 5 and 130 at the N terminus of Tg (6, 7), forming thyroxine within the Tg molecule. Even in the endostyle of protochordates (the earliest species in which thyroid hormone synthesis is known to occur), a Tg-like protein has been reported (8), whereas no other thyroid proteins have yet been discovered to substitute effectively for Tg in this role.

EXPERIMENTAL PROCEDURES

Materials—Lipofectamine 2000, Zysorbin, Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), penicillin, and streptomycin were from Invitrogen. Zysorbin was from Zymed Laboratories Inc. Complete protease inhibitor mixture was from Roche Applied Bioscience. Brefeldin A and protein A-agarose were from Sigma. Protein G-agarose was from EMD Chemicals (Gibbstown, NJ). Dithiothreitol(succinimidyld) propionate was from ThermoFisher Scientific. Peptide-N-glycosidase F was from New England Biolabs. Trans35S-Label was from MP Biomedicals (Irvine, CA). Rabbit polyclonal anticy myc was from Immunology Consultants, Inc. (Newberg, OR). Mouse monoclonal anti-HA epitope was from Covance (Princeton, NJ). Rabbit polyclonal anti-Tg (containing antibodies against epitopes at both N- and C-terminal regions of the protein) has been described previously (17).
Mutagenesis of Mouse Tg—cDNAs encoding secretory ChEL and truncated Tg regions I-II-III (L2169X) and secretory ChEL and ChEL-myc have been described previously (14, 15, 18). Other constructs described in this paper were made using the QuikChange site-directed mutagenesis kit (Stratagene) using following the mutagenic primers paired with their complements: Tg-Q2139X and Q2139X in secretory II-III (5′-GGTTGAGATGTTGTTCTACCCTGATATAGTAATG- CATAACAGTCTCAGGAAGCC-3′); C1973S in secretory II-III-HA (5′-CCATG售后GTTCTTTGAGAGTGAGCGGCT- CTGTGACAGGG-3′); Tg-E1192X (5′-GTTAGGCCACCCA-GCTGTGCTTGTAAGGCACAGTGCACCAGCGTCCC-3′); Tg-Q2135 (5′-CCCAACACCCAGACAGTTGACTG- GGCTGTGAAATGCCC-3′); Tg-Q2139X (5′-CCAGATGGAATCTAAGCCAAGAAGAACAGGGG-3′). To make secretory II-III-HA, a Sall restriction site was introduced into 5′ end of the first type-2 repeat by using a mutagenesis primer and its complement (5′-GGTTGAGATGTTGTTCTACCCTGATATAGTAATG- CATAACAGTCTCAGGAAGCC-3′). The prolactin signal peptide was then fused in-frame at 5′ end of region II using Sall as described previously (15). An HA epitope tag was added using the following primer and its complement (5′-CCGAAGTCTTATCCCTATAGCCTCCAGATTGCTATGACACACCTTCTGACC-3′). I-ChEL was made by introducing Sall sites first, at the 5′ end of the first type-2 repeat as described above and second, at the 5′ end of the ChEL domain using primers described previously (15). The intervening sequence between region I and ChEL was excised by Sall digestion and re-ligation to produce an in-frame I-ChEL construct. For I-II-ChEL, Sall sites were introduced first, at the 5′ end of region III using the following primer and its complement (5′-CCCCAGTCTGACTCCCCGGCTGACAGTCTGGACAGATTGTGTC-3′) and second, at the 5′ end of the ChEL domain as described above. The intervening sequence was excised as above to produce an in-frame I-II-ChEL. Each final product was confirmed by direct DNA sequencing.

Cell Culture and Transfection—HEK293 cells (simply called 293 cells) were cultured in DMEM with 10% FBS in plates at 37 °C in a humidified 5% CO₂ incubator. Plasmids were transiently transfected using Lipofectamine 2000 transfection reagent, following the manufacturer’s instructions.

Metabolic Labeling and Immunoprecipitation—Transfected 293 cells were starved for 30 min in Met/Cys-free DMEM and then pulse-labeled with 180 μCi/ml [35S]-sulfate acids. The cells were then washed with an excess of cold Met/Cys and chased in complete DMEM plus serum. At each time point, cells were lysed by buffer containing 1% Nonidet P-40, 20 mM N-ethylmaleimide, 0.1% SDS, 0.1 M NaCl, 2 mM EDTA, 25 mM Tris, pH 7.4, and a protease inhibitor mixture. For immunoprecipitation, anti-Tg antibody was incubated with cell or media samples overnight at 4 °C, and the immunoprecipitate was recovered with protein A–agarose. For co-immunoprecipitation studies, cells were either cross-linked or prepared without cross-linking in the same lysis buffer lacking SDS and were incubated overnight at 4 °C with immunoprecipitating antibodies and protein A- or protein G-agarose. For cross-linking, cells before lysis were incubated in PBS containing 2 mM dithiobis(succinimidyl) propionate for 30 min at room temperature. Cells were then washed in PBS containing 20 mM N-ethylmaleimide and lysed in buffer containing both 20 mM N-ethylmaleimide and 50 mM glucose to quench residual cross-linker. Immunoprecipitates (or co-precipitates) were washed three times before boiling in SDS sample buffer with or without reducing agent, resolved by reducing SDS-PAGE, and analyzed by fluoroimaging.

RESULTS

Loss of ChEL Rescue upon Loss of an Intact I-II-III—ChEL is known to function as an intramolecular chaperone and escort for I-II-III (15). A stop codon at residue 2,142 of human Tg (equivalent to residue 2,139 of mouse Tg) linked to hypothyroidism (19) truncates a portion of the very last type-3 repeat, creating a naturally occurring I-II-III truncation. To determine whether secretory ChEL is competent to rescue this naturally occurring truncation, we co-expressed these constructs and found comparable intracellular protein expression of recombinant Tg-Q2139X (Fig. 1 lanes 2–5). However, unlike unmutagenized I-II-III (lane 8), secretory ChEL could not rescue Tg-Q2139X (lane 10). Thus, loss of information from the end of region III prevents ChEL-mediated rescue.
To understand this further, we engineered a construct in which region II-III (HA epitope-tagged) immediately follows a signal peptide sequence to direct the protein into the ER. First, we found that II-III-HA was efficiently secreted; and second, we found that introduction of the Q2139X mutation blocked this secretion (Fig. 2A), indicating that Q2139X introduces local misfolding into II-III. However, it is unclear, within the context of full-length Tg, whether II-III local misfolding overrides all other factors to bring about Tg retention in the ER, or whether II-III conformational integrity is needed to help optimize ChEL-mediated facilitation of Tg export (see below).

Japanese patients with mild hypothyroidism and goiter bearing a Tg-C1977S missense mutation (C1973S of mouse, located in domain 3-2b) have been described (20). We found that export of secretory II-III-HA was totally blocked by this mutation, as examined either by pulse-chase experiment (Fig. 2B) or by immunoblotting of collected secretion (Fig. 2C). Importantly, however, in similar experiments Hishinuma et al. clearly showed that a portion of full-length Tg-C1977S molecules does acquire endoglycosidase H resistance, indicating that in the context of the full-length Tg protein, including a wild-type ChEL domain, some rescue of Tg export occurs despite local misfolding caused by mutation in region III (20). These findings seem to argue against the idea that local misfolding within II-III overrides all other factors to bring about Tg retention in the ER. As an alternative, it seemed plausible that II-III may help to optimize ChEL-mediated facilitation of Tg export, and in that case it seemed reasonable to think that II-III and ChEL might directly associate. We therefore chose to examine whether secretory ChEL could assist in the export of wild-type secretory II-III-HA. However, the amount of II-III-HA secreted was unaffected by co-expression of secretory ChEL-myc, again measured either by immunoblotting of collected secretion (Fig. 3A, lanes 2 and 3), and co-precipitation of II-III-HA with ChEL-myc was not detected when the two were co-expressed (lane 5). The positions of molecular mass marker proteins are indicated at left.
labeled cells (Fig. 3B, lanes 2 and 3). Moreover, immunoprecipitation of secreted ChEL-myc could not co-precipitate secreted II-III-HA (Fig. 3A, lanes 2 and 3, and 3B, lanes 4 and 5) even though secretory ChEL-myc does indeed co-precipitate intact I-II-III (15, 21).

Region I Is Incompetent for Secretion—Because II-III and ChEL are both readily secreted, it was important to examine the export of region I alone. Two mouse Tg truncations were prepared for this purpose: E1192X, which contains the first 10 type-1 repeats but no hinge region, and A1435X, which contains these same repeats plus the entire hinge region (see schematic, Fig. 4). There is reason to think that the latter construct might not be secretion-competent because it is so similar to the human Tg-W1418X mutation that has been reported as a heterozygous allele in human hypothyroidism (22). In fact, with or without the ~245-residue hinge, region I alone was incompetent for secretion (Fig. 4), very similar to the behavior of region I-II-III in the absence of ChEL (Fig. 1, lane 7). To explore further the molecular basis for this secretion-incompetence, we performed chemical cross-linking with diithiobis(succinimidyl) propionate to identify ER-interacting proteins associated either with region I alone or region I-II-III in the absence of ChEL. Secretory II-III-HA and secretory ChEL were used as positive controls, and all cells were treated with brefeldin A to prevent any of the proteins from being exported. Impressively, after immunoprecipitation with anti-Tg antibodies and analysis by reducing SDS-PAGE, both I-II-III and region I alone were found to interact selectively with proteins of 94 and 78 kDa, which correspond to ER chaperones GRP94 and BiP (Fig. 5). (Indeed, upon repeat immunoprecipitation with anti-GRP94-and anti-BiP-specific antibodies, identification of both of the cross-linked chaperones was confirmed (data not shown)). By contrast, neither secretory II-III-HA nor secretory ChEL-myc appeared to be appreciably cross-linked to these ER resident proteins (although the SDS-PAGE mobility of secretory II-III is sufficiently close to that of GRP94 that it obscured unequivocal distinction; Fig. 5). The data suggest that in the absence of ChEl facilitation, region I, either alone or embedded within I-II-III, remains conformationally immature, being retained in the ER in association with ER molecular chaperone proteins GRP94 and BiP.

ChEL Interactions with Regions I-II-III, I-II, or Region I Alone—To determine the extent to which ChEL could directly enhance export of upstream regions of Tg, we co-expressed secretory ChEL with either region I alone, I-II, or I-II-III. Co-expression of secretory ChEL did seem to increase the intracellular recovery of each of these newly synthesized constructs (Fig. 6 compare lanes 7–9 with lanes 1–3); however, unlike for I-II-III, secretory ChEL rescue of I-II was minimal (Fig. 6), consistent with the observation that the I-II construct (terminating at mouse Tg-Q1509X) is homologous to the Tg-R1511X mutation reported to be associated with human hypothyroidism (23). In addition, there was no detectable ChEL rescue of I-II (Fig. 6, compare lanes 10–12).

We considered the possibility that direct contiguity of the ChEL domain within the same polypeptide might increase favorable interactions between these regions to enhance secretion. Therefore, we engineered fusion proteins I-ChEL and I-II-ChEL (in contrast to I-II-III-ChEL, which is in fact full-length wild-type Tg). However, direct tethering of the ChEL domain to either region I or I-II did not improve secretory efficiency (Fig.

JOURNAL OF BIOLOGICAL CHEMISTRY 26330 VOLUME 286 © NUMBER 30 • JULY 29, 2011
7) over that observed when secretory ChEL was expressed separately (Fig. 6).

Presumably, the inability of ChEL to improve secretory efficiency of region I or I-II relates at least in part to its (in)ability to make a strong independent contact with these regions. To test this, we examined co-precipitation of metabolically labeled region I or I-II in cells co-expressing secretory ChEL-myc and treated with brefeldin A to block ChEL export. Upon immunoprecipitation, co-expressed I-II-III was efficiently co-precipitated with ChEL (Fig. 8, lane 8), consistent with previous reports (15, 21). Secretory ChEL-myc was also directly immunoprecipitated from other transfections in which it was included, but there was little or no co-precipitation of region I or I-II with ChEL (Fig. 8, lanes 6 and 7).

Because ChEL is unable to rescue region I (or I-II), the foregoing data seemed to suggest that II-III may be required for ChEL-mediated facilitation of Tg export, but this occurs without a strong binary interaction between II-III and ChEL. We therefore triply co-transfected plasmids co-expressing secretory II-III-HA, secretory ChEL, and region I. For the first time (but repeated and confirmed), evidence of rescue of region I secretion was detected (Fig. 9, lane 6). Thus, the data suggest that regions II-III and ChEL both participate in facilitating the maturation and export of region I within Tg.

DISCUSSION

In the last 20 years, ER storage diseases have emerged as one of the central problems in modern secretory biology (24). Qual-
implicated in Tg conformational stability and dimerization, allowing for Tg export from the ER (18). If we wish to understand the mechanism for Tg maturation and export, we must dissect the way in which local domain-specific folding (and folding defects) impact(s) on regional interactions within the larger Tg polypeptide.

In this report, we have discovered that region II-III behaves as a fully competent secretory protein (Fig. 2). These data indicate that II-III can fold independently of the rest of the Tg molecule. Indeed, II-III does not require assistance from secretory ChEL for its export; nor can we find evidence for direct physical interaction of II-III with ChEL (Fig. 3). Further, although a local C1973S mutation in II-III results in a total blockade of secretion (proof of local misfolding; Fig. 2) that same mutation is at least partially suppressed in the context of full-length Tg, which includes a wild-type ChEL domain (20). These findings highlight the importance of regional interactions as an overriding determinant of Tg quality control in the ER.

Interestingly, upon dissection of the Tg molecule, despite being initiated by its natural signal peptide, the data indicate that region I conformational maturation is likely to provide the greatest structural challenge for Tg to become competent for export and thyroid hormonogenesis, because region I alone is intrinsically defective for secretion. This observation is true in the absence of the ensuing hinge sequence (mouse Tg-E1192X) or in its presence (mouse Tg-A1435X), and it is also true for Tg bearing a partial hinge sequence (mouse Tg-L1363X). Indeed, we have learned of a homozygous hypothyroid patient bearing the equivalent human Tg-L1364X mutation,4 and these findings are also consistent with Tg-W1418X as a mutation-linked to human hypothyroidism (22). From our studies, it appears that virtually all of the association of I-II-III with molecular chaperones BiP and GRP94 (a feature linked to Tg retention within the ER) can be attributed to region I alone (Fig. 5). Importantly, this class of truncations cannot be secreted (Fig. 4) even in the presence of secretory ChEL (Fig. 6).

The inability of ChEL to rescue region I is not because of its deployment in trans; indeed, even when directly tethered, ChEL could not promote secretion of region I alone. Although ChEL does exhibit trace rescue of region I-II, it is not until the type-3 repeats are included that ChEL promotion of Tg secretion begins to become efficient (Fig. 7). This conclusion is supported by the inability to detect a stable intracellular interaction between ChEL and either region I or I-II, whereas an obviously stable intracellular association is detected between ChEL and I-II-III (15, 21).

We began these studies by postulating that region III might provide the primary ChEL binding site, but the fact that II-III does not interact with ChEL (Fig. 3) supports a more complex interaction. In our current view, we suggest that structural constraints brought about through binary interactions facilitate conformational stabilization (satisfying ER quality control and export requirements) by promoting ternary complexes of region I, II-III, and ChEL. It is likely that inappropriate or insuf-

4 S. Refetoff, unpublished observation.
icient binary interactions will not support a stabilized and export-competent ternary structure (21). In support of such a view is the finding that only after triple transfection in which secretory II-III and secretory ChEL are co-expressed can secretion of region I begin to become evident (Fig. 9). More studies are needed to map the regional interactions sites, culminating in a complete three-dimensional Tg structure.

REFERENCES
